12.02
-0.88 (-6.82%)
| Penutupan Terdahulu | 12.90 |
| Buka | 12.88 |
| Jumlah Dagangan | 1,381,557 |
| Purata Dagangan (3B) | 488,512 |
| Modal Pasaran | 699,895,808 |
| Harga / Buku (P/B) | 1.19 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Mar 2025 - 17 Mar 2025 |
| EPS Cair (TTM) | -2.84 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.39% |
| Nisbah Semasa (MRQ) | 24.46 |
| Aliran Tunai Operasi (OCF TTM) | -126.81 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -81.79 M |
| Pulangan Atas Aset (ROA TTM) | -20.40% |
| Pulangan Atas Ekuiti (ROE TTM) | -26.53% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Cullinan Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.50 |
|
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.49% |
| % Dimiliki oleh Institusi | 118.80% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (UBS, 149.58%) | Beli |
| Median | 29.00 (141.27%) | |
| Rendah | 28.00 (HC Wainwright & Co., 132.95%) | Beli |
| Purata | 29.00 (141.27%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 16.74 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 24 Oct 2024 | 30.00 (149.58%) | Beli | 15.86 |
| HC Wainwright & Co. | 16 Oct 2024 | 28.00 (132.95%) | Beli | 17.61 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| AHMED NADIM | - | 12.27 | -8,400 | -103,068 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,400 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -103,068 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 12.27 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| AHMED NADIM | Pegawai | 24 Dec 2024 | Jual (-) | 8,400 | 12.27 | 103,068 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |